Evidence shows that engaging in sexualized drug use (SDU) can be associated with sexual health problems and poor mental health. However, the prevalence of drug-related problems associated with SDU remains unclear. Our study aimed to examine the prevalence and associated factors of drug-related problems and drug dependence in a sample of gay, bisexual, and other men who have sex with men living with HIV (HIV + GBMSM). We included 101 HIV + GBMSM who had engaged in SDU in the last year. Participants completed an online survey featuring a validated questionnaire (the DUDIT test) to assess the risk of drug-related problems and drug dependence. Univariate and multivariate analyses were conducted to explore variables associated with drug-related problems. 80% of our sample had symptoms suggestive of drug-related problems, with 5% showing likely drug dependence. Additionally, 10% had suffered an overdose with loss of consciousness, 9% experienced suicidal thoughts associated with SDU, and approximately 20% had sexual difficulties during sober sex since using drugs for sex. Multivariate analysis identified that recent drug use (less than 15 days prior), polydrug use, and depressive symptoms are independent predictors of drug-related problems. Our study revealed a high prevalence of drug-related problems among HIV + GBMSM engaged in SDU. The factors associated with drug-related problems identified in our study can serve as key markers in clinical settings where HIV + GBMSM receive care. These indicators can help detect community members most at risk and facilitate the provision of resources and interventions to prevent SDU-related harm.
Objectives: We assessed the opinions of physicians caring for people with HIV (PWH) from the multicentre Spanish CoRIS cohort regarding the assessment of health‐related quality of life (HRQoL).Methods: We designed an online self‐administered questionnaire comprising 27 structured questions across four domains: (i) sociodemographic and clinical data; (ii) usefulness of measuring HRQoL; (iii) information, training and resource needed; and (iv) whether and how HRQoL should be measured. Physicians completed the questionnaire between April and June 2023.Results: Of 131 physicians surveyed [53.8% men, median age 52 years (interquartile range: 42–60)], 90.9% and 88.6% agreed that measuring HRQoL is useful for both PWH and medical decision‐making, respectively. However, 67.2% needed training on what HRQoL is and how to measure it, 79.4% required information on validated tools, and 80.9% felt that clinical guidelines are needed. Overall, 90.1% of physicians agreed that HRQoL should be measured among PWH. Most physicians (82.8%) supported using specific scales for PWH, with 74.1% recommending annual measurement, 49.1% suggesting that nurses from HIV units conduct the assessments, and 43.1% favouring personal interviews during medical visits. At the time of the survey, 55.3% of physicians did not measure HRQoL in any patients due to time or resource constraints (75.8%).Conclusions: Despite the recognized importance of HRQoL measurement in PWH, Spanish physicians encounter barriers such as time constraints and limited resources. Developing clear guidelines, using tailored scales, and integrating digital tools along with multidisciplinary support could enhance routine HRQoL assessments and improve patient‐centred care.
Multiple sclerosis (MS) and human immunodeficiency virus (HIV) rarely co-occur, suggesting HIV-mediated modulation of MS-related viral immunopathology. This multicentre cross-sectional study analyzed 14 individuals with MS + HIV (HIV → MS, n = 4; MS → HIV, n = 10), alongside HIV-positive individuals on antiretroviral therapy (ART, n = 21), MS (n = 21; 18 on disease-modifying therapies DMTs), and healthy controls (n = 21). IgG/IgM responses to Epstein–Barr virus (EBV), Cytomegalovirus (CMV), human herpesvirus-6 (HHV-6), and human endogenous retrovirus-W envelope (HERV-W env) were quantified by ELISA. HERV-W env expression in PBMC subsets was assessed by FACS/qPCR and flow cytometry (monoclonal antibody CALI222B). Discriminant function analysis (DFA) was used to evaluate a preliminary cohort classification. MS + HIV cohorts displayed higher CMV IgG seroprevalence (95–100% vs. 45% in MS; OR 24.4) and titres. EBNA-1 IgG prevailed in MS and MS + HIV (95–100% vs. 67% in HIV). HERV-W expression was reduced in HIV versus MS, particularly in HIV → MS. Exploratory DFA classified cohorts with 79.6% accuracy (CMV/EBNA-1 primary discriminators). Stepwise analysis identified CMV, EBNA-1, and EBV VCA IgG as main predictors, achieving 100% classification accuracy for MS + HIV (76.4% overall). CMV-dominated profiles distinguish MS + HIV comorbidity, with HIV/ART-associated suppression of EBV/HHV-6 humoral responses and HERV-W gene expression, suggesting an immune remodeling that may explain reduced MS prevalence among people living with HIV.
Background: Long-acting injectable cabotegravir plus rilpivirine (CAB + RPV LA) is an established maintenance option for virologically suppressed people with human immunodeficiency virus-1 (HIV-1), but long-term real-world persistence and virological failure (VF) data remain limited. Methods: RELATIVITY is an ongoing nationwide ambispective multicenter cohort of adults with HIV who switched from suppressive oral antiretroviral therapy to CAB + RPV LA in routine care in Spain. Data through 1 March 2026 were analyzed. The outcomes were virological suppression, treatment persistence, protocol-defined VF, and time to discontinuation-related events. Virological failure was defined as 2 consecutive HIV-1 RNA values ≥200 copies/mL or 1 value ≥500 copies/mL prompting discontinuation. Results: Among 3349 participants, 3343 had valid follow-up dates; the median follow-up was 25.1 months (19.3–30.8). Virological suppression was documented in 3197/3349 (95.5%) overall and 3197/3309 (96.6%) with an evaluable closest viral load; 40 (1.2%) lacked an evaluable value. Injection adherence was ≥90% in 3257/3280 (99.3%) evaluable participants. Overall, 2979/3349 (89.0%) remained on CAB + RPV LA. Virological failure occurred in 28/3349 (0.8%); 20/28 (71.4%) occurred within the first 12 months after switching. Emergent integrase strand transfer inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance was detected in 19/28 VF cases, and 24/28 achieved virological suppression after switching to oral therapy. Treatment-limiting injection-site reactions and systemic adverse events occurred in 2.4% and 1.6%, respectively. Conclusions: Long-acting injectable cabotegravir plus rilpivirine showed high virological suppression and persistence beyond 2 years in routine care. Virological failure was uncommon and clustered mainly within 12 months, supporting early virological monitoring and prompt resistance-guided management.
8 January 2026 in European Journal of Ophthalmology